RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Hepatitis

A collection of news and information related to Hepatitis published by this site and its partners.

Top Hepatitis Articles

Displaying items 1-12
  • The $84,000 hepatitis drug [Letter]

    It was interesting to read that there is now a cure for hepatitis C in the form of new drugs that are capable of completely suppressing the virus in 90 percent of patients in 8 to 12 weeks ("Gilead Sciences' $84,000 price for hepatitis drug is...
  • Another Obamacare goal: Spend money on prevention, save money on cure

    Another Obamacare goal: Spend money on prevention, save money on cure
    Randy Gutzke, a longtime IV drug user who says he struggles daily to stay sober, recently was offered a quick-results test for hepatitis C at a West Side community health center. A case manager also reviewed the behaviors that put him at risk for...
  • Travel abroad to solve the high cost of Hepatitis C medication

    The new Hepatitis C drug costs $84,000 for a 12-week course. In Egypt, it costs $900. Thousands of Americans go to other countries for low-cost medical procedures or treatments . Why don't the insurance companies send the Hepatitis C patients on a 12-week...
  • Despite ridicule, Egypt pushes ahead with AIDS, hepatitis 'cure'

    Egypt’s military on Saturday pressed ahead with promotion of a fanciful device it claims can diagnose and cure AIDS and hepatitis, announcing that it would be tested in the next six months on larger numbers of patients in army hospitals. It was...
  • AbbVie says hepatitis C regimen gets nod for FDA priority review

    AbbVie says hepatitis C regimen gets nod for FDA priority review
    U.S. regulators have granted priority review for AbbVie Inc's experimental all-oral regimen for patients infected with the most common genotype of hepatitis C virus, the company said on Friday. The priority review means the Food and Drug...
  •  

     
     
     
  • New hepatitis C wonder drug shakes up the health care industry

    WASHINGTON When the harsh side effects of his hepatitis C medication forced Joel Roth to stop treatments last year, the only hope for his ailing liver was Sovaldi, a new wonder drug by Gilead Sciences Inc. that would hit the market later that year. In...
  • OraSure expects to be profitable in 2015

    After years of investing millions of dollars in cutting-edge products that determine if people are infected with HIV or hepatitis C, OraSure Technologies of Bethlehem expects to be a profitable enterprise in 2015. It's a major development for the growing...
  • New drugs offer easier, more effective Hepatitis C treatment

    Harvard Health Blog If you're a baby boomer, the U.S. Centers for Disease Control and Prevention (CDC) recommends that you be tested for infection with the hepatitis C virus. The virus can live in the liver for decades, often causing silent damage that...
  • New drugs provide cure for hepatitis C, research finds

    New drugs provide cure for hepatitis C, research finds
    Twenty-five years after scientists first identified the hepatitis C virus, doctors are declaring victory over an infection that afflicts more than 3 million Americans and kills more of them than HIV. In a series of clinical trial results, a new...
  • AbbVie profit jumps 7% on strong Humira sales

    AbbVie profit jumps 7% on strong Humira sales
    AbbVie Inc. posted better-than-expected first-quarter earnings on Friday, propelled by another strong quarter of sales of the blockbuster drug Humira. The North Chicago-based pharmaceutical company said Friday that revenue rose 5.4 percent to $4.56...
  • Legislators Should Dump Doctor Dictate

    Hepatitis C is a health threat that everyone, particularly those in the baby boom generation, needs to take seriously. Nonetheless, a bill now before the General Assembly that would require doctors to offer to provide a hepatitis C screening test to...